AGP Picks
View all

Arkansas Healthcare Report: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Arkansas Healthcare Report.

Press releases published on November 16, 2026

Citizens Commission on Human Rights International Demands Oversight of Elderly Drugging and Protection from Electroshock
Helus Pharma Reports Second Quarter Fiscal 2027 Financial Results and Recent Business Highlights
Alamar Biosciences Highlights NULISA Data in 46 Presentations at CTAD 2026, Including 10 Oral Presentations
Kestra Announces Publication of ACE-PAS, the Largest Prospective Real-World Wearable Defibrillator Study, in the Journal of Cardiovascular Electrophysiology
Zymeworks Announces $200 Million Share Repurchase Authorization
Anteris Announces Late-Breaking PCR London Valves Data Release: One-Year DurAVR THV Outcomes in 100 Patients
Amyotrophic Lateral Sclerosis (ALS) Market Size to Hit US$ 3,986.1 Million by 2033, Coherent Market Insights
Rakovina Therapeutics to Present ATR Inhibitor Data in PTEN-Deficient Prostate Cancer at the 38th EORTC-NCI-AACR Symposium
Vivani Medical Announces Private Placement Equity Financing
EktaH Advances First-in-Class Obesity Treatment NKS-3 into Phase II Clinical Development
Arexera Therapeutics Highlights Potentially Best-in-Class Preclinical Profile and Initiates Clinical Development for ATL-101 in Huntington’s Disease
Cytokinetics Announces Prescribing Information for MYQORZO® (aficamten) Expanded to Include Data from Phase 3 MAPLE-HCM
Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)
Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)
Rejuvenate Biomed Completes Last Patient Visit in Phase 2 Trial of RJx-01 in COPD-Related Muscle Weakness and Advances Regulatory Discussions for Sarcopenia
Philips to nominate Dick Boer, Laurence Debroux and Todd Brinton to its Supervisory Board at the 2027 Annual General Meeting of Shareholders (AGM)
Oculis Announces FDA IND Clearance Enabling Acceleration of Privosegtor Development Program in Acute Multiple Sclerosis Relapses
FOR INVESTORS AND FINANCIAL AND BUSINESS MEDIA ONLY  Renaissance Pharma secures FDA Breakthrough Therapy Designation for daretabart in newly diagnosed high-risk neuroblastoma
Relmada Therapeutics Appoints Uro-Oncology Leader Jørn Skibsted Jakobsen, MD, PhD, as Chief Development Officer
Lakefront Initiates New €50 Million Share Repurchase Program Following Completion of Initial Share Repurchase Program

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Arkansas Healthcare Report

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.